9, RUE DE BITBOURG, LUXEMBOURG, N4
Secures Additional Term Loan Facility of $75 Million
Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Material disclosure
Unaudited Condensed Consolidated Interim Financial Statements as of 31 March 2026 and for the three months ended 31 March 2026 and 2025
Announces Resubmission of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria®, and AVT06, a Proposed Biosimilar to Eylea®
Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
Announces a Change in its Executive Team
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
RW
No filings found
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Free Writing Prospectus
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis